3 Dividend Stocks Worth Buying Now?
Thanks to surging stock prices over the past two years, dividend yields on major stock indices have fallen to fairly low levels. The S&P 500, for instance, currently carries an average yield of just 1.3%.
The mature companies in the Dow Jones Industrial Average fare a bit better, and some of them offer yields that exceed the S&P 500 several times over. » Read more about: 3 Dividend Stocks Worth Buying Now? »
Read More
Market Commentary: $1.7 Billion Fund Bets Massively On 1 Stock
David Einhorn has made a name for himself as the founder of Greenlight Capital, which manages around $1.7 billion at last count in Q3 2023.
Interestingly, the fund has made a massive bet on another company with Green in its name, Green Brick Partners. It’s an unfamiliar name to many investors and even those who do know of it may wonder why such a huge position was established by Einhorn and his investment team.
» Read more about: Market Commentary: $1.7 Billion Fund Bets Massively On 1 Stock »
Read More
Market Commentary: Little-known Dutch Stock Is Soaring
Some stocks just don’t get a lot of notoriety but they deserve the plaudits. In the United States if you were to ask someone to name a digital payment processor, you would likely hear the names Square or Stripe, but the odds are Adyen wouldn’t rank highly in a poll.
It’s with good reason that the Dutch firm flies under-the-radar.
» Read more about: Market Commentary: Little-known Dutch Stock Is Soaring »
Read More
Market Commentary: 1 Unlikely AI Play You Should Not Ignore
When you think of AI plays, Airbnb is not the first company that springs to mind. Yet, Brian Chesky’s firm has made a splash by snapping up GamePlanner.ai for $200 million.
Although it’s not apparent at first glance how artificial intelligence plays into the Airbnb business model, a deeper dive reveals the genius behind the acquisition.
» Read more about: Market Commentary: 1 Unlikely AI Play You Should Not Ignore »
Read More
Massive Upside In Big Money Pharma Favorite?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes in the use of immune therapies for cancer treatment. Specifically, Iovance is exploring new applications of tumor infiltrating lymphocyte (TIL) therapy, utilizing cells that the human body naturally produces to attack cancerous tumors.
There was lots of hype about this next-generation cancer treatment company but its share price has been decidedly lackluster this year,
» Read more about: Massive Upside In Big Money Pharma Favorite? »
Read MoreThe Ivy
5 Stocks Buffett Is Buying and 2 He’s Dumping
In Q4 of last year, Warren Buffett made a few significant changes to the Berkshire Hathaway portfolio. The investing legend sat on the sidelines through much of 2024, with most of his activity accounted for by selling stocks into a high-priced market and consolidating his company’s assets in cash.
With Buffett and his investing team seemingly jumping back into action late last year,
» Read more about: 5 Stocks Buffett Is Buying and 2 He’s Dumping »
Read MoreThe Spotlight
Ignore This Under-the-Radar AI Stock At Your Peril
C3.AI was among the first stocks to bring the idea of artificial intelligence to the forefront of investors’ minds. But it was weighed down by short sellers pointing their arrows at it with claims that have since been contested and refuted.
Today, the company is looking to put those gloomy days in the rearview mirror and anticipates faster growth thanks to its pivoted revenue model,
» Read more about: Ignore This Under-the-Radar AI Stock At Your Peril »
Read MoreThe Daily
Thailand-Cambodia War to end soon? Donald Trump makes BIG statement, says both countries agreed to…, threatens to cut trade deals with….
US President Donald Trump on Saturday announced that both the leaders from Thailand and Cambodia have agreed to meet immediately for ceasefire talks after three days of clashes